Norddjurs municipality in Denmark joins a successful back-to-work program supported by the Monsenso digital health solution

Norddjurs municipality in Denmark joins a successful back-to-work program supported by the Monsenso digital health solution

Norddjurs Municipality in the Central Jutland region joins the successful Return-to-Work program, facilitated by several partners including Empano, Sundinvest, Den Sociale Kapitalfond, AS3, PWC and supported by Monsenso’s digital health solution. From February 2022, Monsenso’s digital health solution will be deployed in Norddjurs Municipality to support individuals during their return-to-work process, while collecting real-world insights on outcomes.

The impact of COVID -19 on social care.
The disruption or shutdown of critical mental health services during the COVID -19 pandemic has led to the rapid adoption of technology-enabled care (TEC) in both health care and adult social care (ASC). Today, there is no doubt that digital technologies offer the potential to improve social care, from targeting resources where they are most needed to promote independence in the community through remote care and treatment support.

Commissioning beyond COVID -19
The adoption of technology-enabled care (TEC) also provides an opportunity to move towards a more person-centered and evidence-based model of commissioning that focuses on service delivery outcomes.

Three forward-thinking municipalities in Denmark implement an outcome-based back-to-work service provided by Empano and Monsenso

To date, two forward-thinking municipalities in Denmark (Guldborgsund and Slagelse) have implemented an outcome-based back-to-work service provided by Empano and Monsenso.

The back-to-work services are designed to help citizens with mental illness return to the labour market faster and consist of coping and motivational courses provided by Empano, offered in conjunction with the Monsenso digital health solution for remote treatment support and real wold data collection on outcomes to validate and demonstrate program effectiveness. 

Since February 2022, Norddjurs municipality in the Central Jutland region has also joined the successful program and more municipalities are expected to follow during the year.

About Monsenso
Monsenso is an innovative technology company offering a medical grade digital health solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment.

To learn more, visit www.monsenso.com

Content Manager

Content Manager

Innovative and ambitious start-up company within personal health technology seeks an equally innovative Content Manager. MONSENSO is a passionate team dedicated to designing innovative personal health technology that helps people, care providers and societies overcome the burden of mental illness.

We are looking for an ambitious Content Manager with a clinical background, who will be responsible for the development of treatment content for the Monsenso platform. You will join the product team acting as both domain expert and sparring partner as well as drive the design of the content strategy and how the product can best support different therapies. You will be involved in the whole lifecycle – from planning, development, structure and design, to involving clinicians and patients in validation activities making sure the content we deliver through the platform is both impactful and engaging.

Key responsibilities

  • Be a facilitator – and in many cases hold the pen – in terms of development, structure and design of treatment content on the Monsenso platform.
  • We imagine that you will be responsible for building “standard” treatment courses within e.g. depression, anxiety, abuse, stress, bipolar disorder etc. in close collaboration with specialists in the various disease areas
  • Plan and perform content validation together with therapists and patients

We expect that you

  • Are a trained psychologist, psychiatrist or nurse – the most important thing, however, is that you can speak the therapist’s language, and know the clinical toolbox
  • Have professional experience from clinical treatment of mental disorders
  • Are experienced and knowledgeable on how treatment methods such as CBT, ACT, DBT can best support patients and work as key supplements to talk therapy and medical treatment
  • Flair for good design and good communication in both Danish and English that engages and moves people
  • Not afraid of the technical aspects in setting up content on our platform (we will of course train you on how it works).

What we offer

  • We offer a fantastic opportunity to join a young and innovative growth company, where you truly have the ability to make an impact and help shape the future in an exciting field. Personal health technology and Digital Health are booming markets worldwide, and you will be at the center of this technology revolution. Mental health is a major burden for society needing new solutions and ways of supporting treatment, and you will contribute to reducing this burden for the benefit of society and the people affected.
  • You should expect an informal, fast-paced environment with tremendous opportunities for personal development.
  • If you have any questions, please contact CPO, Mathias Nick Andersen, andersen@monsenso.com

Company Description

MONSENSO is an experienced team with a proven track record of designing innovative mobile health technology for mental health. We believe in mutual collaboration between patients, care providers and relatives and aim at empowering and inspiring them to engage in achieving better mental health outcomes.
MONSENSO was founded in 2014 based on extensive technological and clinical research in use of mobile technology for mental health. With strong dedication to user-centered innovation, the MONSENSO platform was designed to be easy to use for both patients and clinicians, while at the same time using advanced sensor technology for behavioral data sampling and analysis.

Monsenso digital health solution is HIPAA compliant

Monsenso digital health solution is HIPAA compliant

Monsenso A/S, a technology leader in digital health solutions for mental health is HIPAA compliant. The Monsenso digital health solution that connects individuals and clinicians to provide optimal care adheres to the highest standards for data security and privacy. In addition to being HIPAA compliant, Monsenso holds ISO 13485 and ISO 27001 certifications, Cyber Essentials certification, a TGA certification and class 1 CE mark.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) was enacted by the U.S. Department of Health and Human Services (HHS) and is a federal law that mandates the creation of national standards to protect patients’ sensitive health information from disclosure without their consent or knowledge.

To read more about our data protection, download our Data management & Security fact sheet.

About Monsenso

Monsenso is an innovative technology company offering a digital health solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com.

For additional information contact:

Bettina van Wylich-Muxoll
Chief Marketing Officer
Monsenso
+45 22 70 47 24
marketing@monsenso.com

Product Management & Support Internship

Product Management & Support Internship

Innovative and ambitious company within personal health technology is looking for a product management intern to support company growth.

This is a full-time unpaid internship in Copenhagen for minimum five months (starting date can be discussed) and should be part of the applicant’s education.

Key responsibilities 
 
  • Configuration of the solution to customers (app and web portal)

  • Designing and drafting of app content

  • Assisting in trainings and workshops for clinicians

  • Assisting in product implementation in research projects and commercial clients

  • Maintaining and updating our customer support system

  • Assisting in day-to-day tasks

What we offer

We offer you a fantastic opportunity to join a young company, where you truly have the ability to make an impact and help shape the future in an exciting field. Personal health technology and mHealth are booming markets worldwide. You will have the opportunity to join us on our quest to provide innovative solutions for disease management and treatment support and thereby reduce the burden of mental illness in society. Our informal, fast-paced environment will give you great opportunities to grow professionally and personally.

Desired skills and expertise

  • Taking a degree in Digital Design, Psychology, Healthcare Technology, Communications or another relevant programme. In any case, technical flair is required
  • Service-minded and flexible approach to providing support to customers with varying levels of technical affinity
  • Structured and well-organized way of working, with good attention to detail
  • Good communication skills in English and Danish – orally as well as in writing
  • Able to work independently, yet good interpersonal skills
  • Preferably knowledge about mHealth, health technologies and/or mental health
  • Experience with graphic design or video creation would be a plus
  • Other major languages would be a plus

This is a full-time unpaid internship in Copenhagen, Vesterbro, for minimum five months (Applications are accepted on an ongoing basis, exact start date can be discussed individually)

For questions regarding this position contact Chief Operating Officer, Nanna Iversen by e-mail: iversen@monsenso.com

This internship is only available for students enrolled at a Danish university. To apply for this internship, please submit a Cover letter and your CV to above mentioned contact person.

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development